Dr Julius Cairn. Introduction - update COPD Exacerbations Pulmonary rehabilitation Lung cancer - NSCLC Treatments for patients with limited lung function.

Slides:



Advertisements
Similar presentations
Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.
Advertisements

Treatment.
LIFE-LIMITING ILLNESS
Pulmonary Stereotactic Ablative Radiotherapy:
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Treatment in Advanced Non-Small Cell Lung Cancer.
Professor D. Robin Taylor
Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.
Managing acute exacerbations of COPD in primary care.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp
Advances in the Treatment of Lung Cancer Sin Chong Lau Consultant in Medical Oncology.
Management of Patients With Chronic Pulmonary Disease.
COPD Alison Boland StR Respiratory medicine. Aims & Objectives Overview of COPD Recap basic knowledge Update on COPD Know when to use nebulisers and home.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
IDIOPATHIC PULMONARY FIBROSIS. TREATMENT IN IPF Treatments tried in IPF Antifibrotic Activity Anti-inflammatory Interferon-  1b Pirfenidone Endothelin.
Malignant Pleural Effusions: Treatment with Indwelling Pleural Catheter Luca Bertolaccini 1, Alessandro Berra 2, Emilpaolo Manno 2, Ferdinando Massaglia.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
The role of surgery in the management of mesothelioma Mr Martyn Carr Consultant Thoracic Surgeon Liverpool Heart and Chest Hospital.
Mesothelioma. Is a malignant tumour of pleura, usually resulting from asbestos exposure. Asbestos is the major single cause and there is a history of.
Unity Point Palliative Care Services
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Lung Transplantation Guidelines For Selection Milpark Hospital Transplant Unit Johannesburg, South Africa SATS Controversies Meeting May 2011.
DR MUHAMMAD BILAL NON INVASIVE VENTILATION. DEFINITION : - DELIVERY OF MECHANICAL VENTILATION TO THE LUNGS THAT DON’T REQUIRE ET.T. OR TRACHEOSTOMY IRON.
Respiratory Problems in Post-Polio Syndrome
How can COPD Community Services reduce hospital admissions? Glenda Esmond Respiratory Nurse Consultant West Herts Community COPD Service.
Respiratory failure 31/08/2011 Vivian Ho. Contents Definition Types Pathogenesis Effects Blood gases Management.
يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.
Malignant Pleural Effusion (M.P.E.)
ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.
The Health Roundtable Central Network Respiratory Coordinated Care Program Innovation Presenter: Benjamin Kwan Staff specialist respiratory and sleep medicine.
The Transition to What you need to know for Pulmonary Medicine Date | Presenter Information.
TEMPLATE DESIGN © Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to COPD.
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
นพ. ธรรมศักดิ์ ทวิช ศรี หน่วยเวชบำบัด วิกฤต ฝ่ายวิสัญญีวิทยา รพ. จุฬาลงกรณ์
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
BRONCHOIAL TUMOURS.
Day-case medical thoracoscopy
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Worcester and Wyre Forest Pleural Disease Service Dr. Clare Hooper Consultant Respiratory Physician Worcestershire Acute Hospitals NHS Trust.
LUNG CANCER DR HUDA BADRI. OVERVIEW OF SESSION Learning objectives Quiz Tutorial on lung cancer and guidelines 15 minutes break Case studies 10minutes.
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults British Thoracic Society Intensive Care Society.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Restrictive lung disease
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Lung cancer Gene Kukuy, MD Cardiothoracic Surgery.
Simon Barry Cardiff November 2015
Effective Treatment of Malignant Pleural effusion by Minimal Invasive Thoracic Surgery: Thoracoscopic Talc Pleurodesis and Pleuroperitoneal shunt in 101.
Depart. Of Pulmonology & Critical Care Medicine R4 백승숙.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Survey of acute hospital resources for patients with COPD T McCarthy, M O’Connor, on behalf of the National COPD (Respiratory) Strategy Group Population.
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정.
Clinical Trials in IPF Dr Helen Parfrey. Are clinical trials needed ? Essential to determine if a drug therapy is beneficial Identify who will benefit.
Malignant Pleural Effusion
Emily Tanzler, MD Waseet Vance, MD
Current management of COPD and when to refer?
The Uganda Cancer Institute Experience Walusansa Victoria.
Managing acute exacerbations of COPD in primary care.
Bronchial Carcinoma Part 2
Fig 1A. Patient enrollment flow chart
بنام خداوند جان و خرد.
Early diagnosis of Lung Cancer
Patient Case 1 Patient Case 1: PET/CT Scan.
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
COPD Exacerbations UCI Internal Medicine Mini-Lecture
New Models of Care in Idiopathic Pulmonary Fibrosis
PALLIATIVE CARE FOR COPD PATIENTS:
Presentation transcript:

Dr Julius Cairn

Introduction - update COPD Exacerbations Pulmonary rehabilitation Lung cancer - NSCLC Treatments for patients with limited lung function Tyrosine kinase inhibitors for patients with metastatic adenocarcinoma Treatment of Idiopathic Pulmonary Fibrosis PANTHER-IPF trial

Introduction – service developments Non-invasive ventilation Current acute NIV service Planned Domiciliary service Ambulatory diagnostics/ care for pleural effusion

COPD – exacerbations and importance of pulmonary rehabilitation Impact of exacerbations Sustained decrease in exercise tolerance due to peripheral muscle dysfunction Loss of lung function and ↓ HRQL in frequent exacerbators Not random events, can cluster – high risk in the 8 weeks after first exacerbation Pulmonary rehabilitation Effective after exacerbation – where high risk of readmission Reduces hospital admission No. pts needed to treat to prevent one admission is 4

COPD – management of inflammation, beyond corticosteroids [TORCH - Salmeterol/Fluticasone; Tiotropium] PDE4 inhibitors - Roflumilast Pooled analysis of two large 12 month studies Improves lung function and reduces COPD symptoms Reduces rates of moderate or severe exacerbations Increases time to onset exacerbations in severe to very severe COPD pts who are on LABAs Theophylline – in vitro but not in vivo Macrolides – Azithromycin : 28% ↓ exacerbations ? Statins

Lung cancer NSCLC 75-80% SCLC 20-25% For NSCLC Resection rate 10-20% Stages IA – IIB operable ( 5yr survival IA 69%) Some N2 disease patients are suitable for CHART

Lung cancer – NSCLC limited stage but medically inoperable Treatment for limited stage ca bronchus in patient with limited lung function Stereotactic radiotherapy – stage I (and II) NSCLC 52-83% survival at 2-5 years Small peripheral lesions, medically inoperable, as good as radical DXT Radiofrequency ablation 3 year disease free survival 53% and cancer specific 80% Limited procedure related morbidity – pneumothorax, pleural effusion; no significant fall in lung function for COPD pts

Lung cancer – NSCLC advanced stage – need for detailed pathological and molecular diagnosis Platinum based chemotherapy for stage IIIB and IV Only a 1/3 patients are fit to receive chemo Cisplatin/Pemetrexed for non-squamous Carboplatin/Gemcitabine for squamous ( Bevacizumab + chemo for non-squamous) Advanced adenocarcinoma EGFR mutation status Tyrosine kinase inhibitors eg Gefitinib – as first line treatment –dramatic improvement in progression free survival (PFS), overall response rate 25%

Management of idiopathic pulmonary fibrosis 80,000-85,000 people in Europe Median survival between 2 and 5 years 5 yr survival of 20% Pirfenidone Reduces disease progression by 30% (C) Significantly reduces the decline in VC from baseline(C)

Management of idiopathic pulmonary fibrosis IFIGENIA trial – evaluate the effects of adding N acetyl cysteine (NAC) to patients receiving Azathioprine and Prednisolone Pts receiving NAC for 12 months slower deterioration in VC and DLCO PANTHER-IPF Triple therapy - excess mortality compared to placebo NAC arm still proceeding

Management of idiopathic pulmonary fibrosis Looking for comorbidity Gastro-oesophageal reflux Pulmonary rehabilitation Ambulatory oxygen therapy Pirfenidone NAC Palliative care Specialised clinics Initiation of triple immunosuppressive therapy is now contra-indicated

Service development – Pleural effusion Step 1 - Diagnostics – Pleural Clinic consultation and ultrasound guided procedures speed up diagnosis try to avoid admission to hospital avoid day ward attendance link in with surgical services for thoracoscopy Treatment of malignant pleural effusion Ambulatory care tunnelled indwelling drains – managed through the Pleural Clinic or via short-stay beds Step 2 – Diagnostics - Medical Thoracoscopy Diagnosis and treatment with pleurodesis (currently medical/VATS) Need day case/ short-stay beds – reduced length of stay

Service development – Pleural Clinic Pleural disease clinic Consultations ( first half of a morning clinic) Diagnostic and therapeutic aspirations – via USS Chest drain insertion – via USS Including pleurx or tunnelled indwelling catheters for recurrent malignant effusion

Service development – Non-invasive ventilation Currently Use NIV acutely for decompensated hypercapnic (type II) respiratory failure COPD exacerbation Obesity Hypoventilation syndrome Obstructive Sleep Apnoea with type II respiratory failure Neuromuscular patients

Service development – domiciliary non- invasive ventilation COPD Recurrent admissions with exacerbations and type II respiratory failure Persistent respiratory acidosis when at target oxygenation Sleep disordered breathing Obesity hypoventilation syndrome Type II respiratory failure complicating obstructive sleep apnoea Neuromuscular disease

Conclusion Update in management of three chronic respiratory conditions – focus reducing morbidity & mortality COPD – reducing exacerbations Lung cancer Idiopathic pulmonary fibrosis Service developments in NIV and pleural disease care Shorten the interval to diagnosis and treatment and reduce length of hospital admission